Anastrozole Tablet
Product Images NDC 23155-857

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 23155-857). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avet Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

7b4ba0c5 0287 B7a7 E053 2991aa0a575e

Anastrozole 1 mg oral tablets, round and white, embossed with 'YL' on one side and '111' on the other. These tablets are manufactured by Avet Pharmaceuticals Inc and are prescription medication.*

FDA Label Image

Avet Logo (Avet)

FDA Label Image

30's (Bottle Label 30)

Label for Anastrozole Tablets USP 1 mg from Avet Pharmaceuticals Inc. The label indicates 30 tablets in the package, with a prescription-only status. The label includes dosage and storage information, manufacturer details, NDC 23155-857-03, and a barcode.*

FDA Label Image

500's (Bottle Label 500)

Label for Anastrozole Tablets USP, 1 mg strength, in a package of 500 tablets. The product is prescription-only, manufactured by Avet Pharmaceuticals Inc. The label includes the NDC 23155-857-05, storage instructions, and manufacturing details indicating control by Beijing Bio-engineering Technology Co., Ltd.*

FDA Label Image

90's (Bottle Label 90)

Label for Anastrozole Tablets, USP 1 mg oral tablets by Avet Pharmaceuticals Inc. The label indicates a package containing 90 tablets. It includes the NDC 23155-857-09, prescription-only status, storage instructions, manufacturer information, and a barcode. The label features blue and white colors with the Avet Pharma logo.*

FDA Label Image

Chemical Structure For Anastrozole (Image 01)

Chemical structure diagram of anastrozole, showing its molecular framework with ring systems and chemical bonds consistent with the active ingredient anastrozole in tablet form.*

FDA Label Image

Figure 1 (Image 02)

A Kaplan-Meier survival curve chart depicting disease-free survival over time in months for patients treated with anastrozole versus tamoxifen. The y-axis represents the proportion of patients alive and disease-free, ranging from 0 to 1. Both treatments show similar survival proportions over approximately 90 months. A table below the graph shows the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Image 03)

A line graph comparing disease-free survival over time (in months) between patients treated with anastrozole and tamoxifen. The y-axis shows the proportion alive and disease-free, while the x-axis represents survival duration in months. Patient numbers at risk for both treatments are listed below the graph at various time points.*

FDA Label Image

Figure 3 (Image 04)

A Kaplan-Meier survival curve chart comparing Anastrozole and Tamoxifen over 120 months, showing the proportion event free on the y-axis and time to event in months on the x-axis. The chart includes a table of the number of patients at risk for both treatments at various month intervals up to 120 months.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier survival plot depicting the proportion of patients event-free over time up to 120 months, comparing two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents time to event in months, and the y-axis represents the proportion event-free. Below the plot is a table showing the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 5 (Image 06)

This is a survival curve plotting the proportion not progressing against time in months for two randomized treatments, Anastrozole and Tamoxifen. The X-axis represents time to progression in months up to about 42 months, and the Y-axis represents the proportion not progressing from 0.0 to 1.0. The graph shows two step curves comparing progression-free proportions for the two treatments over time, with a legend and number at risk below the graph for each treatment group at several time points.*

FDA Label Image

Figure 6 (Image 07)

A survival curve chart comparing time to progression (months) for two randomized treatments, Anastrozole and Tamoxifen. The y-axis represents the proportion not progressing, and the x-axis shows time in months from 0 to 42. Both treatments exhibit similar progression profiles over time, with the proportion not progressing declining steadily. The chart includes sample sizes at risk below the x-axis for each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.